JP2022081686A - Medicine for intestinal disorders, antiallergic agent, immunoadjuvant, and agent for improving enteroadherent properties of lactic acid bacteria - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a medicine for intestinal disorders, an antiallergic agent, an immunoadjuvant and an agent for improving enteroadherent properties of lactic acid bacteria, which can be taken safely, are available inexpensively, and have high effect of improving enteroadherent properties of lactic acid bacteria.

SOLUTION: An agent according to the present invention contains flower extract. The flower is a Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae flower, preferably, at least one selected from Carthamus tinctorius, Punica granatum, Pueraria plants, Subgen. Cerasus plants, Chrysanthemum plants, Crocus sativus, Prunus persica Batsch and Rosa plants.

SELECTED DRAWING: Figure 1

COPYRIGHT: (C)2022,JPO&INPIT

Description

The present invention relates to an intestinal regulator, an antiallergic agent, an immunopotentiator, and an intestinal adhesiveness improving agent for lactic acid bacteria.

It is well known that promoting the growth of lactic acid bacteria in the intestinal tract of animals can suppress the invasion of pathogenic bacteria and the growth of harmful bacteria, and that such an intestinal regulating action leads to improvement or prevention of diarrhea and constipation. It is considered that the adhesion (adhesion) of lactic acid bacteria in the intestinal tract is very important for the lactic acid bacteria to settle and proliferate in the intestinal tract.

Furthermore, in recent years, it has been reported that lactic acid bacteria are also associated with antiallergic effects.
In the human immune system, multiple types of T cells play the role of a control tower. As T cells, Th1 cells that mainly promote IgA antibody production and activate cell-mediated immunity and Th2 cells that promote IgE antibody production that causes type I allergy and activate humoral immunity are known. The Th1 cells and Th2 cells suppress each other, and when Th2 cells act predominantly over Th1 cells, allergic symptoms are likely to occur.
It is said that 70% of the immune cells in the body are concentrated in the intestinal tract, and play a major role in the body's immune system. It has been elucidated that lactic acid bacteria play an important role in this intestinal immunity. For example, it is known that the bacterial cell component of lactic acid bacteria promotes cytokine secretion of macrophages and dendritic cells in the intestinal tract, thereby activating the function of Th1 cells and promoting IgA antibody production. It is believed that this suppresses the action of Th2 cells, suppresses IgE antibody production, and improves allergies. Adhesion of lactic acid bacteria (and their cell components) to the intestinal tract is considered to be very important for enhancing such intestinal immunostimulatory action and the associated antiallergic action.

Therefore, if an oral agent that improves the intestinal adhesion of lactic acid bacteria can be used to promote the intestinal adhesion of lactic acid bacteria, intestinal regulation and prevention and improvement of antiallergic can be expected. Such oral preparations are required to be highly safe and available at low cost, but their development has not progressed and they have not fully responded to the diverse needs of patients and consumers.

On the other hand, flower extracts are used in health foods and the like, and various actions have been studied so far (for example, Patent Document 1), but new uses are required.

Japanese Patent Application Laid-Open No. 2003-055249

Therefore, an object of the present invention is to provide a new lactic acid bacterium intestinal adhesiveness improving agent, intestinal regulating agent, antiallergic agent and immunopotentiating agent.

The present inventors have diligently studied substances capable of enhancing the intestinal adhesiveness of lactic acid bacteria. As a result, it was found that the intestinal adhesiveness of lactic acid bacteria can be enhanced by using a specific flower extract as an inexpensive and safely available material.

The present invention is based on the above findings, and is an intestinal regulator containing an extract of flowers of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. It is to provide.

The present invention also comprises an antiallergic agent, an immunopotentiator and an extract of flowers of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. It provides an agent for improving intestinal adhesion of lactic acid bacteria.

According to the present invention, there are provided an intestinal regulating agent, an antiallergic agent, an immunopotentiating agent, and an intestinal adhesiveness improving agent for lactic acid bacteria, which can be safely ingested, can be obtained at low cost, and have an excellent effect of improving intestinal adhesiveness of lactic acid bacteria.

Further, according to the present invention, since a specific flower extract has high intestinal adhesion to lactic acid bacteria, the action of lactic acid bacteria in the intestinal tract can be enhanced by ingesting it orally, which is excellent in diet, beauty and health promotion. The effect can be expected.

FIG. 1 is a graph showing the results of evaluating the intestinal adhesive action of the agents of Examples 1 to 5 and Comparative Example 1. FIG. 2 is a graph showing the results of evaluating the intestinal adhesive action of the agents of Examples 6 to 10 and Comparative Example 1.

Hereinafter, the present invention will be described based on the preferred embodiment thereof. The agent of the present invention is an extract of a flower (hereinafter, also referred to as a specific flower) of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. It contains.
Unless otherwise specified, the following description applies to any of the intestinal regulators, antiallergic agents, immunopotentiators and lactic acid bacteria intestinal adhesion improvers of the present invention.

(Flower extract)
The present invention effectively enhances intestinal adhesion of lactic acid bacteria by using flowers of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. Can be done.

Pomegranate (Pomegranate, Stone) is preferably mentioned as the Lythraceae. Pomegranate is a deciduous tree belonging to the genus Pomegranate of the Lythraceae family, and its scientific name is Punica granatum.

Safflower (red flower) and chrysanthemum (chrysanthemum) are preferably mentioned as the Asteraceae. Safflower refers to an annual or perennial herb of the genus Carthamus in the family Asteraceae. The scientific name is Carthamus tinctorius.
Chrysanthemum is a plant of the genus Chrysanthemum in the family Asteraceae. As the chrysanthemum, a chrysanthemum (scientific name: Chrysanthemum morifolium Ramatulle) or a chrysanthemum (scientific name: Chrysanthemum indicum Linne) of the genus Chrysanthemum of the family Chrysanthemum is preferably mentioned.

As the legume family, kudzu is preferably mentioned. Kudzu is a plant of the genus Pueraria in the family Leguminosae. Examples of the waste include Pueraria thomsonii (scientific name: Pueraria thomsonii), Pueraria lobata (scientific name: Pueraria lobata), and Pueraria sumbergiana (scientific name: Pueraria thunbergiana).

Preferred examples of the Rosaceae include cherry blossoms (cherry blossoms, sakura), peaches (peaches), and roses (roses).
Sakura is a general term for plants belonging to the genus Cerasus of the Rosaceae family, excluding plums, peaches, apricots, etc., and generally refers to plants belonging to the subgenus Cerasus.
Peach belongs to the genus Plum of the Rosaceae family, and its scientific name is Prunus persica Batsch or Prunus persica Batsch var. Davidiana Maximowicz. Examples of peach varieties include hakuto (white peach), outou (yellow peach), nectarine and the like.
Rose refers to a plant belonging to the genus Rosa of the Rosaceae family.

As the Iridaceae, saffron (scientific name: Crocus sativus) is preferably mentioned. Saffron is a perennial of the Iridaceae family native to the Mediterranean coast.

The flower may be a flower collected at any stage from the bud to the fully opened flower. Further, the flower after flowering may be the whole flower, or may be one or more of petals, calyxes, stamens, pistils, stigmas, and flower beds (in the immature stage). For example, it is preferable to use a pistil as the saffron, and it is preferable to use a bud as the waste.

Examples of the extraction treatment for obtaining these flower extracts include treatment using an extraction solvent such as water or an organic solvent. Examples of the extraction solvent include polar solvents. Examples of the polar solvent include water, methanol, ethanol, isopropanol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, acetic acid, ethyl acetate, ether, hexane and the like. Of these, water, methanol, ethanol, and hydrous ethanol are preferable. It should be noted that these may be used alone or in combination of two or more. In addition, squeezing raw flowers without using an extraction solvent is also included in the extraction process.

Extraction may be carried out on fresh flowers, or on flowers that have been dried, heated, cut or crushed. The extraction solvent may or may not be heated at the time of extraction, but the solvent temperature at the time of heating is not particularly limited, and is a temperature generally used for obtaining a flower extract, for example, 40 ° C. or higher. Below the boiling point. For example, if it is water, it may or may not be hot water. Hot water refers to water having a temperature of 70 ° C. or higher.

The obtained extract is subjected to treatments such as dilution, concentration, drying and purification to obtain an extract as a final processed product. Examples of the purification method include methods such as activated carbon treatment, resin adsorption treatment, silica gel treatment, ion exchange resin, liquid-liquid countercurrent distribution, and membrane separation. The flower extract of the present invention may be obtained through a fermentation process (for example, a fermentation process of a pre-extraction raw material or a fermentation process of an extract), or a product obtained without these fermentation processes. May be.

In the agent of the present invention, the specific flower extract may be in the form of liquid, paste, gel or solid, and the solid form is preferable from the viewpoint of quality stability and the like. Examples of the solid state include powder, granule, granule, fine grain, tablet, rod, plate, block, solid and the like.

It is particularly preferable that the agent of the present invention contains at least one selected from pomegranate, safflower, kudzu, cherry, saffron, peach and rose as a specific flower extract because the intestinal adhesive action of lactic acid bacteria is particularly high.

The specific flower extract in the agent of the present invention preferably has a dry mass of 0.0001% by mass or more, more preferably 0.0005% by mass or more and 50% by mass or less, in the agent of the present invention. , 0.001% by mass or more and 30% by mass or less is particularly preferable.

The agent of the present invention may consist substantially only of a specific flower extract as a plant-derived component, or may have other plant-derived components. For example, the plant-derived component other than the specific flower extract in the agent of the present invention is preferably 80% by mass or less, more preferably 50% by mass or less in the agent of the present invention.

The agent of the present invention may not contain lactic acid bacteria, but it is preferable that the agent contains lactic acid bacteria from the viewpoint of further enhancing the intestinal adhesive effect of lactic acid bacteria. When the lactic acid bacterium is a live bacterium, it is preferable from the viewpoint of improving the intestinal environment, but it may be a dead bacterium. This is based on the fact that not only live bacteria but also the bacterial cell components of dead bacteria stimulate intestinal immunity, and that the bacterial cell components of dead bacteria feed on live lactic acid bacteria. It is also known that lactic acid bacteria, which are dead bacteria, adsorb harmful substances in the intestinal tract. The lactic acid bacterium used in the present invention is not particularly limited as long as it produces lactic acid as a metabolite, and examples thereof include those conventionally orally ingested in animals such as humans, and examples thereof include Bifidobacterium, Lactbacillus, and the like. Examples include those of the genera Enterococcus, Leuconostoc, Pediococcus, Staphylococcus, Tetragenococcus, and Bacillus.
Examples of the genus Bifidobacterium include Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium adolescentis, and Bifidobacterium mongoliense.
Lactbacillus属としては、Lactbacillus brevis、Lactbacillus gasseri、Lactobacillus acidophilus、Lactobacillus buchneri、Lactobacillus bulgaricus、Lactobacillus delburvecki、Lactobacillus casei、Lactobacillus crispatus、Lactobacillus curvatus、Lactobacillus halivaticus、Lactobacillus pentosus、Lactobacillus plantarum、Lactobacilus paracasei、Lactobacillus rhamnosus、Lactobacillus salivarius、 Lactobacillus sporogenes, Lactobacillus sakei, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus reuteri, Lactobacillus fermentum.
Enterococcus includes Enterococcus faecalis (sometimes referred to as Streptococcus faecalis), Enterococcus faesium (sometimes referred to as Streptococcus faesium), Streptococcus thermophilus, and Lactococcus lactis (sometimes referred to as Streptococcus lactis). Will be.
Examples of the genus Leuconostoc include Leuconostoc mesenteroides and Leuconostoc oenos.
Examples of the genus Pediococcus include Pediococcus acidilactici and Pediococcus pentosaceus.
Examples of the genus Staphylococcus include Staphylococcus carnosus and Staphylococcus xylosus.
Examples of the genus Tetragenococcus include Tetragenococcus halophilus. Examples of the genus Bacillus include Bacillus coagulans and Bacillus mesentericus.
In particular, Bacillus coagulans, Enterococcus faecalis, Bifidobacterium bifidum, Enterococcus faesium, and Lactobacillus acidophilus are preferable. These may be used alone or in combination of two or more.

When the agent of the present invention contains lactic acid bacteria, the content of the lactic acid bacteria is not particularly limited, but for example, the number of cells in the agent of the present invention is 1 × 103 or more, preferably 1 × 105 or more and 1 × 1020. Hereinafter, it is more preferable that the number is 1 × 107 or more and 1 × 1015 or less from the viewpoint of ease of preparation and enhancement of the intestinal adhesion effect of lactic acid bacteria.

When the agent of the present invention contains lactic acid bacteria, the lactic acid bacteria and the extract of a specific flower may be contained in the same agent or may be contained in different agents. When contained in separate agents, the agent of the present invention is a multi-dose form of two or more agents. When contained in the same agent, the agent of the present invention may be a one-drug type or a multi-drug type, but the one-drug type is preferable in terms of ease of ingestion and the like. The dosage form of the agent of the present invention may be solid, liquid, paste, gel or the like regardless of whether it is a one-agent type or a multi-agent type. For example, as solids, powders, granules, granules, tablets, rods, plates, blocks, solids, capsules such as hard capsules and soft capsules, capsules, tablets, chewables, sticks, etc. Each form of is mentioned. Examples of the liquid include a fluid and a syrup. These can be formulated into various dosage forms by a known formulation method by adding a pharmaceutically acceptable base material or carrier.

For example, the preferred dosage form of the agent of the present invention containing lactic acid bacteria includes lactic acid bacteria and the extract of the specific flower, and is in the form of powder, fine granules, granules, tablets, capsules such as soft capsules and hard capsules. The first dosage form, which is either liquid or contains the above-mentioned specific flower extract, is powdery, fine-grained, granular, tablet-like, capsule-like such as soft capsules and hard capsules, and liquid first preparation. , A two-dosage form containing lactic acid bacteria, powdery, finely granular, granular, tablety, capsule-like such as soft capsules and hard capsules, and a second agent which is either liquid or the like. In the present invention, the intestinal adhesiveness of lactic acid bacteria and bifidobacteria present in the intestine can be improved by using the first agent containing the specific flower extract alone. When the agent of the present invention is divided into two agents, the preferable ratio of the extract of a specific flower in the agent of the present invention described above can be a ratio to the total amount of the two agents.

The oral ingestion method of the agent of the present invention is not limited, and the agent may be ingested as it is, or may be ingested by dispersing or dissolving the agent in water, hot water, milk, yogurt or the like. When the agent of the present invention is in a multi-dose form, a plurality of agents may be ingested at the same time, or may be ingested at different timings. When ingesting at a different timing, for example, the lactic acid bacterium-containing agent may be ingested before the flower extract-containing agent, and conversely, the flower extract-containing agent may be ingested before the lactic acid bacterium-containing agent. However, the time difference between the two intakes is preferably within 24 hours, more preferably within 18 hours, and particularly preferably within 15 hours. The method of ingesting the two agents may be the same or different. If they are different, for example, the lactic acid bacterium-containing agent is ingested as it is, and the flower extract-containing agent is dispersed in water, hot water, milk, yogurt, etc. There is an example of ingesting, and this may be the opposite.

In addition to the specific flower extract and lactic acid bacteria, the agent of the present invention may contain other commonly used components as long as the effects of the present invention are not impaired. Such ingredients include various excipients, binders, brighteners, lubricants, stabilizers, diluents, bulking agents, thickeners, emulsifiers, antioxidants, pH regulators, colorants, fragrances. , Additives and the like. The content of other components can be appropriately selected depending on the form of the agent of the present invention and the like. Further, when the agent of the present invention is in a multi-dose form, which agent contains which other component is appropriately selected according to the form of the agent.

The daily oral dose of the agent of the present invention is preferably 0.1 mg or more as the dry mass of the extract of the specific flower. The agent of the present invention can be administered continuously, for example daily, and may be continuously administered for a long period of time, for example, for one month or longer.

Whether or not the agent of the present invention contains lactic acid bacteria, the daily oral dose of lactic acid bacteria is 1 × 103 or more, particularly 1 × 105, assuming the oral dose of the specific flower extract. More than 1 × 1020
It is preferably less than or equal to.

As is clear from the description of Examples described later, the agent of the present invention can enhance the intestinal adhesiveness of lactic acid bacteria by the action of the specific flower extract. The term "intestinal adhesiveness" as used herein preferably means adhesion to intestinal epithelium (intestinal epithelial cells). The intestinal adhesiveness may be the adhesiveness of individual lactic acid bacteria, or the adhesiveness of lactic acid bacteria as an aggregate (the ratio of intestinal adhesive (adhered) bacteria in the aggregate).
Therefore, the agent of the present invention can enhance the action of lactic acid bacteria in the intestinal tract by ingesting it orally, and can be used, for example, as an intestinal regulating agent. Examples of the intestinal regulating action include an action of promoting the growth of beneficial intestinal bacteria (including lactic acid bacteria) and an action of suppressing the growth of harmful intestinal bacteria. For example, the laxative action of peach flowers and the anti-constipation action using the same described in Patent Document 1 are not included in the intestinal regulating action referred to in the present invention. Further, for example, the anti-inflammatory action brought about by PPAR activation is not included in the intestinal regulating action referred to in the present invention.

Since the agent of the present invention can enhance the intestinal adhesion of lactic acid bacteria, it can be used as an immunopotentiator for intestinal immunity, and rashes such as atopic dermatitis, allergic rhinitis, hay fever, eczema, and urticaria. , It is possible to prevent or improve allergic symptoms such as diarrhea and vomiting. The action of the immunopotentiator includes activating the function of Th1 cells in the intestinal tract and promoting IgA antibody production.

The agent of the present invention is suitably applied to humans, but animals other than humans (for example, mice, rats, hamsters, dogs, cats, cows, pigs) as long as the respective actions and effects are exhibited. , Monkeys, etc.).

Examples of the lactic acid bacterium to be targeted for enhancing the intestinal adhesiveness (adhesion) by the agent of the present invention include the same lactic acid bacteria as those mentioned above as the lactic acid bacterium that may be contained in the agent of the present invention. The present invention further provides foods or pharmaceuticals containing the agents of the present invention, quasi-drugs, and the like.
The present invention provides a method (excluding medical practice) of ingesting the agent of the present invention together with lactic acid bacteria to promote adhesion of lactic acid bacteria in the intestinal tract.

Hereinafter, the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited to such examples. Hereinafter, unless otherwise specified, "%" represents mass% and "parts" represents mass parts.

[Examples 1 to 10, Comparative Example 1]
(Test substance)
The following powders were used as specific flower extracts.
・ Benibana: Commercially available extract powder obtained by extracting Benibana flowers with water ・ Kuzu: Commercially available extract powder obtained by extracting Kuzu flowers with hot water ・ Rose: Rose petals Commercially available extract powder obtained by extracting with hot water ・ Pomegranate: Pomegranate flower extracted with hydrous ethanol, commercially available extract powder ・ Sakura: Sakura flower extracted with hydrous ethanol Commercially available extract powder, Kiku: obtained by extracting Kiku flowers with water, commercially available extract powder, Saffron: obtained by extracting saffron mess with hydrous ethanol, commercially available Extract powder ・ Momo: Commercially available extract powder obtained by extracting white peach blossoms with hot water.

(Adhesive ability test)
(1) Culture and dissemination of human colon cancer-derived cells Caco-2 (1-1) Passage 20 intestinal epithelial cell line Caco-2 cells were used.
(1-2) Caco-2 cells suspended by trypsin treatment were seeded from a 75 cm2 flask into a 96 well plate at a cell density of 4.0 × 104 / well.
(1-3) Using a culture medium, the cells were cultured at 37 ° C. in a 5 volume% CO2 incubator for 4 days. This normal medium was prepared so that DMEM was 10% FBS (Fatal Bovin Serum), 1% penicillin-streptomycin, and 1% NEAA (Non-Essential Amino Acids, SIGMA). By this culture, a monolayer membrane (intestinal tract model) of caco-2 was prepared in the well.
(1-4) The test medium was replaced with a test medium several hours before the test of (5). The test medium was prepared so that DMEM was 2% FBS and 1% NEAA.

(2) Bacillus coagulans glycerol stock and preculture (2-1) Powdered lactic acid bacterium Bacillus coagulans was cultured in MRS liquid medium for 72 hours at 37 ° C.
(2-2) The culture broth was collected, mixed with the culture broth so that the glycerol content was 30%, and stored at -80 ° C until the test was performed (glycerol stock).
(2-3) The glycerol stock of B. coagulans is returned to room temperature, seeded in an MRS liquid medium warmed at 37 ° C., cultured at the same temperature for 24 hours, and then for the fluorescent label of (3) below and the calibration curve of (4). It was used to prepare a sample.

(3) Fluorescent labeling of B. coagulans (3-1) After pre-culturing B. coagulans in (2), 100 μL of the bacterial solution was collected and suspended in 900 mL of phosphate buffered saline (PBS), 1000 g. × Centrifuged for 3 minutes. The obtained pellet was suspended in 1000 μL PBS, 15 μL carboxyfluorescein diacetate (CFDA, manufactured by Dojin Chemical Research Institute) was added, and the mixture was incubated for 30 minutes at room temperature.
(3-2) Centrifugation was performed at 1000 g x 3 minutes, the pellet was suspended in 1 mL PBS, and the pellet was centrifuged again at 1000 g x 3 minutes. This operation was performed twice.
(3-3) The pellet was suspended in a test medium, and the obtained suspension was used in the test of (5) below.

(4) Preparation of sample for calibration curve (4-1) A part of the lactic acid bacteria fluorescently labeled in (3-1) above was fixed with formalin.
(4-2) The same pre-cultured sample was cultured in BCP medium at 37 ° C. for 3 days, and the number of colonies on the BCP medium was measured (plate count).
(4-3) The number of bacteria was calculated from the plate count, and the sample fixed with formalin in (4-1) was used as a known number sample and used as a calibration curve sample.

(5) Fixation ability comparison test (5-1) 10 mg of flower extract powder, which is the test substance in Table 1 below, was weighed, placed in a 50 mL falcon tube, and a test medium was added to a concentration of 1 mg / mL. After vortexing, the test medium was diluted with the test medium so that the final concentration of each test substance was the concentration shown in Table 1 below.
(5-2) In (5-1), a bacterial suspension adjusted to a bacterial count of 1x108 / mL was added to the test medium containing or not containing the test substance to obtain a B. coagulans concentration of 1x106 / mL. The cells of (1-4) were added in an amount of 100 μL per well (B. coagulans final concentration 1x105 / well) and cultured at 37 ° C. for 2 hours. In Comparative Example 1, the same amount of test medium containing no test substance was added.
(5-3) After completion of the culture, 150 μL formalin solution was added to each well, and the cells were fixed at 4 ° C. for 30 minutes or longer.
(5-4) The well was washed twice with PBS, and the fluorescence intensity (excitation light 495 nm, fluorescence 515 nm) was measured with varioskan.
(5-5) A calibration curve was prepared by measuring the fluorescence intensity of the calibration curve sample of (4-3) with varioskan. Based on the obtained calibration curve, the number of B. coagulans adhered to the Caco-2 monolayer membrane was calculated from the fluorescence intensity measured in (5-4).
(5-6)
The relative values (%) of the obtained bacterial numbers with respect to Comparative Example 1 are shown in FIGS. 1 and 2.

From the results of FIGS. 1 and 2, it can be seen that the specific flower extract enhances the intestinal adhesion rate of lactic acid bacteria. In addition, since the agent of the present invention has high intestinal adhesion to lactic acid bacteria, the action of lactic acid bacteria in the intestinal tract can be enhanced by ingesting it, and the intestinal regulating action, antiallergic action, immunopotentiating action, diet, etc. It can be expected to have excellent effects on beauty and health promotion.

Claims (4)

An intestinal regulator containing at least one flower extract selected from Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. An antiallergic agent containing an extract of at least one flower selected from Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. An immunopotentiator containing at least one flower extract selected from Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. An intestinal adhesion improver for lactic acid bacteria containing at least one flower extract selected from Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae. ..

Images